TG TherapeuticsTGTXTOP PICKNov 18, 2026Stock price when the opinion was issued
As of Nov 18, 2026. Market Open.
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
Note that biotech is very risky and very volatile, so tread carefully. In general, you want class-leading drugs, optionality for bigger markets or "other indications", reasonable valuation compared to potential sales.
(Analysts’ price target is $69.43)Its drug treats Multiple Sclerosis, and uses new research to target the appropriate cells (not T cells as before). MS affects ~2.9M people globally. Approaching $1B in revenue. Catalyst is in-home use of the MS drug. No dividend.